Drug Profile
Insulin intranasal - Adhera Therapeutics
Alternative Names: Insulin Nasal Spray - MDRNALatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Nastech Pharmaceutical Company
- Developer Marina Biotech
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 09 Oct 2018 Marina Biotech is now called Adhera Therapeutics
- 07 Aug 2015 No recent reports on development identified - Phase-II for Type-2 diabetes mellitus in USA (Intranasal)
- 01 Apr 2010 MDRNA acquires Cequent Pharmaceuticals and is renamed Marina Biotech